UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Biotage’s (STO:BIOTA) Board of Directors and Torben Jörgensen have agreed to extend Torben Jörgensen’s current employment contract as Biotage’s CEO and President up and until April 2019 when Torben Jörgensen will be 67 years old. According to the previous agreement Torben Jörgensen would leave Biotage April 2017.
Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08.30am on September 21, 2015.
About Biotage
Biotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by government authorities, academic institutions, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has approx. 290 employees and had sales of 490 MSEK in 2014. Biotage is listed on the NASDAQ OMX Stockholm stock exchange. Website: www.biotage.com
This information was brought to you by Cision http://news.cision.com
Contacts
Biotage
Ove Mattsson
Chairman of the Board
Tel: +46
73-372 72 80
